BIGBEAR
PHARMACEUTICAL
Ponatinib is a tyrosine kinase inhibitor that exerts its effect by selectively inhibiting the activities of BCR-ABL fusion protein and various other kinases.
AuthenticGuaranteeFast DeliveryPrivacy Sortorasirb (AMG510) is a highly selective targeted drug against KRASG12C mutations, developed by Amgen. It received accelerated approval from the US ···【More】
Update: 18 Mar,2026Source: BigbearViews: 98
Sotoprazib (AMG510), a specific inhibitor of KRASG12C, can cause various adverse reactions in the treatment of non-small cell lung cancer.Common Side ···【More】
Update: 18 Mar,2026Source: BigbearViews: 97
Ponatinib Precautions and Drug InteractionsPonatinib is a third-generation BCR-ABL tyrosine kinase inhibitor developed and manufactured by Takeda Phar···【More】
Update: 18 Mar,2026Source: BigbearViews: 95
Ponatinib's Efficacy and ActionsPonatinib is a tyrosine kinase inhibitor that inhibits tumor cell proliferation by targeting and inhibiting the ac···【More】
Update: 18 Mar,2026Source: BigbearViews: 98
Ponatinib is an oral medication mainly used for the treatment of specific types of chronic myeloid leukemia and acute lymphoblastic leukemia. It inhib···【More】
Update: 04 Mar,2026Source: BigbearViews: 92
Ponatinib is a third‑generation tyrosine kinase inhibitor (TKI) indicated for the treatment of chronic myeloid leukemia (CML) and Philadelphia chromos···【More】
Update: 04 Mar,2026Source: BigbearViews: 87
Copyright2024@ BIGBEAR All right reserved Bigbear | Bigbear Pharmaceutical | Bigbear Laos
